The primary management strategy of SCD remains focused on symptom control, and despite significant progress in understanding the condition, haematopoietic stem cell transplantation (HSCT) remains the only curative option (Lucarelli et al., in utero management, drastically changing the paradigm for SCD treatment before birth
A poorly functioning nervous system
Helps Reduce Toxin Reabsorption: Binding agents help prevent recirculation of toxins in the body.*
Longer-term clinical studies and real-world evidence will be essential to better characterize the safety profile of cagrilintide-semaglutide, particularly regarding uncommon adverse events, treatment persistence, and its effects on body composition and bone health
However, self-reported anxiety symptoms may limit the generalizability of the findings
Need further proof that it's worth your money